Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 18/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.48 |
| ▸ | MTOR | P42345 | 5/20 | 0.48 |
| ▸ | PRKDC | P78527 | 2/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596472 | 0.90 | ATR (0.61) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL3599561 | 0.88 | ATR (0.53) | ATRPIK3CAMTORPRKDC | |
| SCHEMBL3591060 | 0.86 | PIK3CD (0.47) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL3600401 | 0.86 | ATR (0.44) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL3596951 | 0.81 | ATR (0.53) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL3596955 | 0.79 | ATR (0.49) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL3803211 | 0.78 | ATR (0.53) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL3607383 | 0.78 | PIK3CA (0.40) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL3607289 | 0.76 | PIK3CB (0.39) | ATRPIK3CAPIK3CD | |
| SCHEMBL3607016 | 0.76 | ATR (0.47) | ATRPIK3CAMTORPRKDCPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | claimed |
| EP-2146981-A1 | PHARMACEUTICAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-27 | — | — | EP | claimed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | claimed |
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| EP-2146981-A1 | PHARMACEUTICAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, JAK2 | ATR 957/4885PIK3CA 1/4885MTOR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.